# A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

> **NCT07182149** · PHASE1 · RECRUITING · sponsor: **Normunity AccelCo, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- HNSCC
- ESCC
- Esophageal Adenocarcinoma
- Gastric Adenocarcinoma
- GEJ Adenocarcinoma
- Ovarian Cancer
- NSCLC
- Cervical Cancer
- Endometrial Cancer
- Triple Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** NRM-823

## Key facts

- **NCT ID:** NCT07182149
- **Lead sponsor:** Normunity AccelCo, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-30
- **Primary completion:** 2027-05-30
- **Final completion:** 2028-10-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07182149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07182149, "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07182149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*